A Randomised, Single Dose, 5-period, 5-treatment, Crossover Study to Assess the Relative Bioavailability of 4 Different Formulations of Verinurad and Allopurinol in Healthy Subjects

This study is a single centre, randomised, open-label, single-dose, 5-period, 5-treatment, crossover study in healthy male and female subjects. This study is intended to assess the relative bioavailability between the fixed dose combination (FDC, i.e. verinurad/allopurinol FDC capsule 12/300 mg) and free combination formulations of verinurad (i.e. verinurad prolonged release Hydroxypropyl methylcellulose [HPMC] capsule 12 mg) and allopurinol (i.e. allopurinol table 300 mg) in fasted and fed conditions. The study will also assess the relative bioavailability between a formulation only containing verinurad (i.e. verinurad prolonged release gelatin capsule 12 mg) and the FDC capsule.

开始日期2021-04-13

申办/合作机构

AstraZeneca PLC

[+1]

NCT04532918

/ Completed临床1期

An Open-label, 3-Treatment, 3-Period, Fixed Sequence Study in Healthy Subjects to Assess the Pharmacokinetics of Verinurad and Allopurinol When Administered Alone, and in Combination With Single Doses of Cyclosporine or Rifampicin

This Phase 1 study aims to quantify the effects of cyclosporine, a broad transporter inhibitor, and rifampicin, an OATP1B1/3 inhibitor, on verinurad pharmacokinetics (PK). The study is conducted in accordance with Food and Drug Administration guidance on Clinical Drug Interaction Studies, 2020. Verinurad will be developed as a fixed combination since it will always be administered together with allopurinol.

开始日期2020-09-10

申办/合作机构

AstraZeneca PLC

[+1]

NCT04327024

/ Completed临床2期

A Phase 2, Multicentre, Double-Blind, Placebo and Active Control Efficacy and Safety Study to Evaluate Verinurad Combined With Allopurinol in Heart Failure With Preserved Ejection Fraction

International, Multicenter, Double-Blind, Placebo and Active Control Efficacy and Safety Study to Evaluate Verinurad combined with Allopurinol in Heart Failure with Preserved Ejection Fraction

开始日期2020-05-19

申办/合作机构

AstraZeneca PLC

100 项与 Verinurad 相关的临床结果

登录后查看更多信息

100 项与 Verinurad 相关的转化医学

登录后查看更多信息

100 项与 Verinurad 相关的专利（医药）

登录后查看更多信息

项与 Verinurad 相关的文献（医药）

2024-10-01·JAMA Cardiology

The AMETHYST Randomized Clinical Trial

Article

作者: Källgren, Christian ; Shah, Sanjiv J. ; Mentz, Robert J. ; Sjöström, C. David ; Voors, Adriaan A. ; Myte, Robin ; Lewis, Gregory D. ; Kitzman, Dalane W. ; Kaguthi, Grace ; Perl, Shira

ImportanceElevated serum uric acid (SUA) level may contribute to endothelial dysfunction; therefore, SUA is an attractive target for heart failure with preserved ejection fraction (HFpEF). However, to the authors’ knowledge, no prior randomized clinical trials have evaluated SUA lowering in HFpEF.ObjectiveTo investigate the efficacy and safety of the novel urate transporter–1 inhibitor, verinurad, in patients with HFpEF and elevated SUA level.Design, Setting, and ParticipantsThis was a phase 2, double-blind, randomized clinical trial (32-week duration) conducted from May 2020 to April 2022. The study took place at 59 centers in 12 countries and included patients 40 years and older with HFpEF and SUA level greater than 6 mg/dL. Data were analyzed from August 2022 to May 2024.InterventionsEligible patients were randomized 1:1:1 to once-daily, oral verinurad, 12 mg, plus allopurinol, 300 mg; allopurinol, 300 mg, monotherapy; or placebo for 24 weeks after an 8-week titration period. Allopurinol was combined with verinurad to prevent verinurad-induced urate nephropathy, and the allopurinol monotherapy group was included to account for allopurinol effects in the combination therapy group. All patients received oral colchicine, 0.5 to 0.6 mg, daily for the first 12 weeks after randomization.Main Outcomes and MeasuresKey end points included changes from baseline to week 32 in peak oxygen uptake (VO2), Kansas City Cardiomyopathy Questionnaire total symptom score (KCCQ-TSS), and SUA level; and safety/tolerability (including adjudicated cardiovascular events).ResultsAmong 159 randomized patients (53 per treatment group; median [IQR] age, 71 [40-86] years; 103 male [65%]) with median (IQR) N-terminal pro–brain natriuretic peptide level of 527 (239-1044) pg/mL and SUA level of 7.5 (6.6-8.4) mg/dL, verinurad plus allopurinol (mean change, −59.6%; 95% CI, −64.4% to −54.2%) lowered SUA level to a greater extent than allopurinol (mean change, −37.6%; 95% CI, −45.3% to −28.9%) or placebo (mean change, 0.8%; 95% CI, −11.8% to 15.2%; P &lt; .001). Changes in peak VO2 (verinurad plus allopurinol, 0.27 mL/kg/min; 95% CI, −0.56 to 1.10 mL/kg/min; allopurinol, −0.17 mL/kg/min; 95% CI, −1.03 to 0.69 mL/kg/min; placebo, 0.37 mL/kg/min; 95% CI, −0.45 to 1.19 mL/kg/min) and KCCQ-TSS (verinurad plus allopurinol, 4.3; 95% CI, 0.3-8.3; allopurinol, 4.5; 95% CI, 0.3-8.6; placebo, 1.2; 95% CI, −3.0 to 5.3) were similar across groups. There were no adverse safety signals. Deaths or cardiovascular events occurred in 3 patients (5.7%) in the verinurad plus allopurinol group, 8 patients (15.1%) in the allopurinol monotherapy group, and 6 patients (11.3%) in the placebo group.Conclusions and RelevanceResults of this randomized clinical trial show that despite substantial SUA lowering, verinurad plus allopurinol did not result in a significant improvement in peak VO2 or symptoms compared with allopurinol monotherapy or placebo in HFpEF.Trial RegistrationClinicalTrials.gov Identifier: NCT04327024

2024-05-01·Journal of the American Society of Nephrology

Combination Treatment with Verinurad and Allopurinol in CKD

Article

作者: Inker, Lesley A. ; Sjöström, C. David ; Jongs, Niels ; Eklund, Olof ; Rikte, Tord ; Stack, Austin G. ; Terkeltaub, Robert ; Perkovic, Vlado ; Perl, Shira ; Bjursell, Magnus ; Heerspink, Hiddo J.L. ; Maklad, Noha

Key Points

The SAPPHIRE trial was designed to assess albuminuria-lowering effects of the urate transporter 1 inhibitor verinurad combined with allopurinol in patients with CKD.

Verinurad 3, 7.5, and 12 mg in combination with allopurinol 300 mg did not reduce albuminuria during 34 weeks treatment compared with allopurinol alone or placebo.

Verinurad/allopurinol combination dose-dependently reduced serum urate concentrations compared with placebo.

BackgroundHyperuricemia is associated with elevated risks of cardiovascular and chronic kidney disease (CKD). Since inhibition of urate transporter 1 has been suggested to be potentially nephroprotective, we performed a phase 2b study to assess albuminuria-lowering effects of the urate transporter 1 inhibitor verinurad combined with the xanthine oxidase inhibitor allopurinol in patients with CKD and hyperuricemia.MethodsIn this randomized placebo and active controlled trial, we enrolled participants with serum urate concentrations ≥6.0 mg/dl, eGFR ≥25 ml/min per 1.73 m2, and a urinary albumin-creatinine ratio (UACR) 30–5000 mg/g to one of five treatment arms: placebo, placebo+allopurinol 300 mg/day, verinurad 3 mg+allopurinol 300 mg/day, verinurad 7.5 mg+allopurinol 300 mg/day, or verinurad 12 mg+allopurinol 300 mg/day in a 1:1:1:1:1 ratio. The primary end point was the change in UACR from baseline to 34 weeks. Secondary end points were changes from baseline in UACR at week 60 and changes in serum urate and eGFR at weeks 34 and 60.ResultsBetween August 2019 and November 2021, 861 adults with CKD (mean age 65 years, 33.0% female, mean eGFR 48 ml/min per 1.73 m2, median UACR 217 mg/g) were enrolled. At 34 weeks, the geometric mean percentage change in UACR from baseline did not differ among treatment groups (16.7%, 95% confidence interval [CI], −0.6 to 37.1 in the 3 mg group, 15.0% [95% CI, −1.85 to 34.6] in the 7.5 mg group, 14.0% [95% CI, −3.4 to 34.4] in the 12 mg group versus 9.9% [95% CI, −6.6 to 29.4] in the allopurinol group, and 37.3% [95% CI, 16.6 to 61.8] in the placebo group). UACR and eGFR change from baseline did not differ among treatment groups after 60 weeks. Verinurad/allopurinol combination dose-dependently reduced serum urate concentrations compared with placebo. The proportion of patients with adverse events and serious adverse events was balanced among treatment groups.ConclusionsVerinurad in combination with allopurinol did not decrease UACR or eGFR decline, but further reduced serum urate compared with allopurinol alone or placebo.Clinical Trial registry name and registration number:SAPPHIRE Trial registration number, NCT03990363.

2023-12-02·Expert Opinion on Drug Metabolism & Toxicology

Overview of the pharmacokinetics and pharmacodynamics of URAT1 inhibitors for the treatment of hyperuricemia and gout

Review

作者: Song, Danni ; Mao, Jiale ; Hou, Zihan ; Ma, Aijinxiu ; Zhao, Xu

INTRODUCTIONHyperuricemia is a common metabolic disease, which is a risk factor for gouty arthritis and ureteral stones and may also lead to cardiovascular and chronic kidney disease (CDK). Therefore, hyperuricemia should be treated early. Xanthine oxidase inhibitors (XOIs) and uricosuric agents (UAs), which target uric acid, are two types of medications that are used to treat gout and hyperuricemia. XOIs stop the body from producing excessive uric acid, while UAs eliminate it rapidly via the kidneys. Urate transporter 1 (URAT1) belongs to the organic anion transporter family (OAT) and is specifically localized to the apical membrane of the epithelial cells of proximal tubules. Unlike other organic anion transporter family members, URAT1 identifies and transports organic anions that are primarily responsible for urate transport.AREAS COVEREDThis article reviews the pharmacokinetics and pharmacodynamics of the existing URAT1 inhibitors to serve as a reference for subsequent drug studies.EXPERT OPINIONThe URAT1 inhibitors that are currently used as clinical drugs mainly include dotinurad, benzbromarone, and probenecid. Results indicate that RDEA3170 may be the most promising inhibitor, in addition to SHR4640, URC-102, and MBX-102, which are in the early stages of development.

项与 Verinurad 相关的新闻（医药）

2021-11-12

·Endpoints

AstraZeneca expects 'modest profitability' for next round of Covid-19 vaccine supply deals — and prunes pipeline in Q3 update

Having sent 1.5 billion Covid-19 vaccines around the world on a not-for-profit basis, AstraZeneca says it’s time to move into “modest profitability.” While the priority is to deliver all the “pandemic doses” — a total of 3 billion are set to be delivered by the end of the year — AstraZeneca expects to be taking new orders in Q4, leading to a blend in sales. “Don’t expect massive profitability, which is sometimes the case for other vaccine makers,” Ruud Dobber, head of the biopharmaceuticals business unit, told Endpoints News . Mene Pangalos, his counterpart on the R&D side, added that low-income countries will still be able to get the vaccine, whether as the primary series or a booster, at the not-for-profit price under its tiered pricing arrangements. The pivot, which has been teased in previous comments, is among multiple updates disclosed in the company’s Q3 earnings report. AstraZeneca also noted those expected profits will offset costs of its long-acting antibody program, which is being reviewed by several regulatory agencies. Despite coming late in the race, Pangalos believes antibody will play a big role by filling the gap between vaccines and treatments like oral antivirals. “Others are talking about prophylaxis, but they’re talking about monthly administration, we’re talking about, potentially, at a maximum twice a year. I’m hoping it’ll be once a year,” he said, adding in the treatment setting, “you won’t just be treated for the two weeks that you’ve got the symptoms, you’ll be treated the next 12 months in terms of prevention. I know what I would take.” As is custom for these seasonal announcements, AstraZeneca also revealed some pruning of the pipeline. The team is dropping two Phase II combo trials anchored by its PD-L1 Imfinzi: One had tested Imfinzi together with MEDI0457, a DNA HPV vaccine, in head and neck squamous cell carcinoma. The other involved chemotherapy and imaradenant — which it had licensed from Sosei Heptares in 2015. Its removal, according to Sosei Heptares, may mean the drug is returning where it came from. Finally, out goes verinurad, the URAT1 inhibitor that was being tested for chronic kidney disease and heart failure with a preserved ejection fraction, which Pangalos said just didn’t look as good as everything else in the pipeline. “Post Alexion acquisition, we’ve spent a lot of time reviewing all of the opportunities,” Pangalos said. “We have the scientific merits, the business cases, the revenues, the timing, and obviously, you know, wanting to be disciplined in terms of R&D spend, which is already being pushed to the limit, because the opportunities that we have, we had to deprioritize certain assets.” Here’s some of those programs they are prioritizing and ushering into Phase I and II:

疫苗抗体并购

2021-04-23

·BioSpace

Uric Acid Drugs Market: Rise in the incidence and prevalence of gout and other related disorders to drive the market

Uric acid is produced in the body after the metabolic breakdown of purine nucleotides. An excess uric acid in the body leads to a chronic inflammatory condition known as gout. An excess of uric acid leads to the formation of crystals in the body, which eventually leads to the deposition of uric acid crystals in joints, resulting in inflammation and pain. Read Report Overview - It also leads to other medical condition such as diabetes, kidney stones, hyperparathyroidism, bone marrow disorders, and others. Excess uric acid leads to swollen joints, pain, heat, redness, and joint stiffness. Symptoms start with the inflammation of the big toe. However, an excess of uric acid can affect several joints of the body such as ankles, fingers, heels, wrists, knees, and elbows. Symptoms are more prevalent in men compared to women. Problems due to uric acid are more prevalent in developed countries as compares to other parts of the world. In 2013, uric acid problems affected around 5.8 million people, or about 1%-2% of the total population in the western world. Request Brochure of Uric Acid Drugs Market Report - The global uric acid drugs market can be segmented based on drug, distribution channel, and geography. Based on drug, the global uric acid drugs market can be classified into allopurinol, febuxostat, and probenecid. In terms of distribution channel, the uric acid drugs market can be categorized into online pharmacies, retail pharmacies, and hospital pharmacies. The hospital pharmacies and retail pharmacies segments are expected to hold a key share of the uric acid drugs market, due an increase in the number of hospital visits and stays. The online pharmacies segment is anticipated to expand at a high CAGR during forecast period, due a rise in the number of Internet users and ease of use of these pharmacies. Request for Analysis of COVID-19 Impact on Uric Acid Drugs Market – Rise in the incidence and prevalence of gout and other related disorders, increased research and development expenditure, and growing awareness among people are projected to boost the global uric acid drugs market in the coming years. Moreover, there is a strong ongoing clinical pipeline of drugs that reduce uric acid levels in the body. For instance, SEL 212 by Selecta Biosciences, verinurad by Ardea Biosciences, URC-102 by JW Pharmaceutical, and others. This is likely to further drive the uric acid drugs market during the forecast period. However, sideeffects associated with current treatment and disappointing results of promising pipeline molecules are expected to hamper the global uric acid drugs market during the forecast period. Pre-book Uric Acid Drugs Market Report -

100 项与 Verinurad 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11129	-	-	DB11873

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
慢性肾病	临床2期	以色列	AstraZeneca PLC	2019-07-23
慢性肾病	临床2期	美国	AstraZeneca PLC	2019-07-23
慢性肾病	临床2期	罗马尼亚	AstraZeneca PLC	2019-07-23
慢性肾病	临床2期	法国	AstraZeneca PLC	2019-07-23
慢性肾病	临床2期	匈牙利	AstraZeneca PLC	2019-07-23
慢性肾病	临床2期	意大利	AstraZeneca PLC	2019-07-23
白蛋白尿	临床2期	美国	AstraZeneca PLC	2017-05-18
2型糖尿病	临床2期	美国	AstraZeneca PLC	2017-05-18
高尿酸血症	临床2期	日本	AstraZeneca PLC	2014-01-05
痛风	临床2期	美国	Ardea Biosciences, Inc.	2013-08-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04327024 (AMETHYST, Pubmed \| JAMA Cardiol) 人工标引	临床2期	射血分数保留型心力衰竭	159	Verinurad plus Allopurinol	(糧網鏇鑰遞廠齋遞選醖) = 鬱顧選齋醖糧選窪壓窪艱糧範繭簾積壓餘夢糧 (窪築選膚鏇鏇壓醖顧蓋, -0.56 ~ 1.10) 更多	不佳	2024-08-14
				Allopurinol	(糧網鏇鑰遞廠齋遞選醖) = 窪鏇膚網衊餘遞憲艱繭艱糧範繭簾積壓餘夢糧 (窪築選膚鏇鏇壓醖顧蓋, -1.03 ~ 0.69) 更多
NCT04327024 (AMETHYST, CTgov)	临床2期	射血分数保留型心力衰竭	159	Placebo for verinurad	鹽繭衊積獵憲鬱鹹獵鏇(製艱鏇積衊膚鹹膚範鏇) = 簾憲鬱網糧遞廠獵艱鹽蓋夢醖餘鏇齋糧蓋窪醖 (壓觸觸淵製願夢餘遞構, 範遞顧構壓構襯夢餘願 ~ 齋獵範積襯網鹹壓觸艱) 更多	-	2023-06-29
NCT04550234 (CTgov)	临床1期	慢性肾病	25	Verinurad prolonged release HPMC capsule+Allopurinol Tablet (Treatment 1)	醖構範襯鑰繭製廠簾鹹(糧餘繭鏇獵餘衊淵衊鑰) = 積廠淵衊簾選憲鹹壓鬱夢廠願鑰觸鑰夢積鑰鬱 (窪遞築範選鏇顧襯壓網, 鑰範蓋範膚壓鏇範鏇衊 ~ 淵餘製壓築廠願鹹餘餘) 更多	-	2023-05-10
				Verinurad/Allopurinol FDC Capsule (Treatment 2)	醖構範襯鑰繭製廠簾鹹(糧餘繭鏇獵餘衊淵衊鑰) = 範夢淵憲襯獵鏇遞糧顧夢廠願鑰觸鑰夢積鑰鬱 (窪遞築範選鏇顧襯壓網, 襯襯簾鏇襯顧糧範襯淵 ~ 鬱襯夢鹽膚襯願鏇蓋範) 更多
NCT04532918 (CTgov)	临床1期	慢性肾病	14	Verinurad+Allopurinol (Period 1: Verinurad + Allopurinol)	鏇鏇壓鏇觸鑰壓鏇鏇願(齋獵糧餘鑰齋範餘範憲) = 選顧積憲網糧窪淵壓鹹繭繭獵廠衊簾鬱襯鑰壓 (鑰鏇膚窪網膚鬱夢淵衊, 觸獵觸觸醖築憲遞選範 ~ 襯繭夢獵淵齋糧鹹鹹糧) 更多	-	2023-03-27
				Verinurad+Cyclosporine+Allopurinol (Period 2: Verinurad + Allopurinol + Cyclosporine)	鏇鏇壓鏇觸鑰壓鏇鏇願(齋獵糧餘鑰齋範餘範憲) = 壓憲鑰鏇夢廠襯選蓋製繭繭獵廠衊簾鬱襯鑰壓 (鑰鏇膚窪網膚鬱夢淵衊, 糧餘鑰鹽顧憲顧鏇齋簾 ~ 顧簾壓簾鏇鏇淵窪衊衊) 更多
NCT04256629 (CTgov)	临床1期	慢性肾病	24	ER8+verinurad+allopurinol (Treatment A)	簾夢衊齋簾選觸構醖構(鑰繭遞憲糧遞觸艱構選) = 淵窪製範築積壓鹹襯膚鏇壓糧糧壓鏇餘餘簾遞 (鏇廠蓋網鑰艱衊築觸壓, 顧選艱窪鬱艱願淵壓簾 ~ 襯願壓範壓網鏇網窪築) 更多	-	2022-01-31
				verinurad+allopurinol (Treatment B)	簾夢衊齋簾選觸構醖構(鑰繭遞憲糧遞觸艱構選) = 範襯鏇繭選願鑰簾顧壓鏇壓糧糧壓鏇餘餘簾遞 (鏇廠蓋網鑰艱衊築觸壓, 糧齋鬱膚鹹糧醖鹹繭選 ~ 夢鬱選憲鑰壓淵鹹構蓋) 更多
NCT03316131 (Pubmed \| J Clin Endocrinol Metab) 人工标引	临床2期	高尿酸血症	36	verinurad+febuxostat+dapagliflozin	窪顧糧窪膚鹽獵範積鏇(窪齋範膚觸築顧網築積) = 壓夢齋鑰顧製艱艱簾鹽積獵網觸網糧糧築齋餘 (選簾觸繭艱膚築獵鑰鏇, -21.0 ~ -4.7) 更多	积极	2021-04-23
				Placebo+verinurad+febuxostat	窪顧糧窪膚鹽獵範積鏇(窪齋範膚觸築顧網築積) = 膚遞夢壓製夢鹽遞網鬱積獵網觸網糧糧築齋餘 (選簾觸繭艱膚築獵鑰鏇, -21.3 ~ -5.0) 更多
NCT04024501 (CTgov)	临床1期	慢性肾病	25	ER8 (Treatment 1: 1 x 12 mg ER8 Capsule Fasted)	顧醖網襯醖壓廠窪選構(鏇蓋夢鏇窪壓蓋膚夢顧) = 製齋艱築膚艱範願範鏇構膚膚夢衊襯淵壓築衊 (製鑰遞鏇襯範淵餘餘簾, 選鹹蓋憲鹹夢鏇餘鑰淵 ~ 網獵鬱襯壓窪餘糧構築) 更多	-	2020-08-21
				verinurad A (Treatment 2: 2 x 6 mg A-capsule Fasted)	顧醖網襯醖壓廠窪選構(鏇蓋夢鏇窪壓蓋膚夢顧) = 鬱醖憲遞築膚廠獵醖窪構膚膚夢衊襯淵壓築衊 (製鑰遞鏇襯範淵餘餘簾, 網繭鹹醖鏇鏇築膚鑰膚 ~ 鹽簾窪範鹽壓蓋襯積網) 更多
NCT03118739 (SP262 \| URATE-LOWERING THERAPY WITH VERINURAD AND FEBUXOSTAT, CTgov)	临床2期	高尿酸血症 \| 2型糖尿病 \| 白蛋白尿	60	Verinurad+Febuxostat (Verinurad 9 mg+Febuxostat 80 mg)	(願顧艱製蓋糧選廠醖窪) = 夢顧選構獵鹹衊顧顧網襯艱顧構製構範製積築 (遞遞廠積製糧餘網鹹壓, 繭鹽廠構齋獵窪蓋夢鹽 ~ 繭夢選餘鏇窪鹹淵蓋願) 更多	-	2020-01-10
				Placebo (Placebo)	(願顧艱製蓋糧選廠醖窪) = 積簾願顧醖鬱觸製衊願襯艱顧構製構範製積築 (遞遞廠積製糧餘網鹹壓, 遞遞鑰淵衊蓋襯齋願鏇 ~ 觸膚憲製衊鹽膚淵範簾) 更多
NCT02078219 (CTgov)	临床2期	高尿酸血症 \| 痛风	204	RDEA3170 (RDEA3170 Treatment Group 1)	製選壓壓鏇選製窪淵夢(觸鏇醖廠壓醖積夢築齋) = 醖餘觸遞鹹獵齋獵蓋鏇憲壓壓鏇齋憲艱鹹鏇範 (範鏇獵壓鏇廠艱鑰夢構, 鏇簾選壓積簾構齋廠選 ~ 網鬱鏇簾淵齋蓋構繭願) 更多	-	2019-09-24
				RDEA3170 (RDEA3170 Treatment Group 2)	製選壓壓鏇選製窪淵夢(觸鏇醖廠壓醖積夢築齋) = 顧範鹽醖構製範遞鹹構憲壓壓鏇齋憲艱鹹鏇範 (範鏇獵壓鏇廠艱鑰夢構, 鏇艱製糧壓鬱構餘艱願 ~ 餘簾淵壓衊繭餘製壓鑰) 更多
NCT03316131 (QUARTZ, CTgov)	临床2期	高尿酸血症	36	verinurad+febuxostat+dapagliflozin (Treatment Sequence A+B)	憲壓衊艱壓鑰構積衊繭(夢醖淵壓蓋齋艱簾願憲) = 衊網範鹹構選選窪築淵鹹積夢鑰夢構餘膚願觸 (憲製憲顧願憲襯衊鬱醖, 構鏇遞艱艱窪膚鹽築艱 ~ 艱觸艱夢餘齋範鹹鹽膚) 更多	-	2019-07-18
				placebo+verinurad+febuxostat (Treatment Sequence B+A)	憲壓衊艱壓鑰構積衊繭(夢醖淵壓蓋齋艱簾願憲) = 觸鑰繭壓網觸襯顧壓糧鹹積夢鑰夢構餘膚願觸 (憲製憲顧願憲襯衊鬱醖, 鏇鹽鹹鹽廠餘觸壓願顧 ~ 壓鬱積鹹鏇遞繭鬱膚願) 更多